Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- OTC NEWS IN BRIEF
September 1, 2003
- BUSINESS NEWS IN BRIEF
September 1, 2003
- DIAGNOSTIC NEWS IN BRIEF
September 1, 2003
- WEBSITE NEWS
September 1, 2003
- MEDICAL DEVICE NEWS IN BRIEF
September 1, 2003
- Financial Results in 1st Quarter
September 1, 2003
- WORLD NEWS IN BRIEF
September 1, 2003
- Semianual Financial Results
September 1, 2003
- Yamanouchi Licenses Bone Morphogenetic Protein to Medtronic Sofamor Danek
September 1, 2003
- JST Outsources 4 High-risk Projects to Companies
August 25, 2003
- REGULATORY NEWS IN BRIEF
August 25, 2003
- JT Positions Pharma Business as Pillar in Next Generation
August 25, 2003
- TRI to Increase Staff Members to 150: Seminar
August 25, 2003
- Wives in Their 20s Having Greater Number of Children: Survey
August 25, 2003
-
August 25, 2003
- PRESS SEMINAR
August 25, 2003
- 31 Mono-drugs, 7 Combination Drugs Designated for Quality Reevaluation
August 25, 2003
- Yamanouchi to Beef Up Marketing to Gain 6% Share: President Takenaka
August 25, 2003
- DIAGNOSTIC NEWS IN BRIEF
August 25, 2003
- 31 Ingredients Designated for 26th Quality Reevaluation
August 25, 2003
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…